SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon surges as its arm gets nod from Health Canada for Micafungin for injection

11 May 2026 Evaluate

Biocon is currently trading at Rs. 393.25, up by 12.70 points or 3.34% from its previous closing of Rs. 380.55 on the BSE.

The scrip opened at Rs. 348.05 and has touched a high and low of Rs. 396.00 and Rs. 348.05 respectively. So far 501960 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 317.90 on 12-May-2025.

Last one week high and low of the scrip stood at Rs. 396.45 and Rs. 338.00 respectively. The current market cap of the company is Rs. 63734.09 crore.

The promoters holding in the company stood at 44.91%, while Institutions and Non-Institutions held 31.59% and 23.49% respectively.

Biocon’s subsidiary -- Biocon Pharma has secured approval from Health Canada for Micafungin for injection, USP, 50 mg and 100 mg. The approved product is indicated for use in adults and children four months and older for treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections; treatment of patients with esophageal candidiasis; and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. The approval will further strengthen the company’s integrated biosimilars and generics portfolio.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

418.55 1.75 (0.42%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: